SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses.
Meghan K HerringJames K RomineMeredith G WesleyKatherine D EllingsonSarang K YoonAlberto J Caban-MartinezJennifer MeeceManjusha GaglaniLauren GrantLauren E W OlshoHarmony L TynerAllison L NalewaySana M KhanAndrew L PhillipsNatasha Schaefer SolleSpencer RoseJosephine MakSammantha B FullerAngela HuntJennifer L KuntzShawn BeitelYoung M YooPearl Q ZhengGayatri AraniJulie Mayo LamberteTaylor EdwardsMark G ThompsonRyan SprisslerNatalie J ThornburgAshley A LoweTamara PilishviliJennifer L UhrlaubKaren LutrickJefferey L BurgessAshley L FowlkesPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
A third dose of mRNA vaccine typically elicited a robust humoral immune response among those with primary vaccination regardless of SARS-CoV-2 infection >3 months prior to boosting. Those with infection < 3 months prior to boosting did not have a significant increase in antibody concentrations in response to a booster.